AnaptysBio, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a ANAB research report →
Range $70 – $95
Price Chart
About the company
AnaptysBio, Inc. , a clinical-stage biotechnology company, focuses in delivering immunology therapeutics for autoimmune and inflammatory diseases in the United States. The company’s products include Rosnilimab, a selective pathogenic T cell deplete which completed a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis; ANB033, a CD122 antagonist, which is in a Phase 1b trial for celiac disease and eosinophilic esophagitis; ANB101, a BDCA2 modulator antibody which is in Phase 1a trial that specifically targets plasmacytoid dendritic cells and inhibits interferon secretion and modulates antigen presentation; dostarlimab, a PD-1 antagonist for various solid tumor indications; and Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 development for the treatment of generalized pustular psoriasis.
- CEO
- Daniel Faga
- IPO
- 2017
- Employees
- 104
- HQ
- San Diego, CA, US
Get TickerSpark's AI analysis on ANAB
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $1.46B
- P/E
- 7.29
- Fwd P/E
- 20.33
- PEG
- -0.00
- P/S
- 6.13
- P/B
- 136.02
- EV/EBITDA
- 17.39
- Div Yield
- 0.00%
- Gross Margin
- 133.11%
- Op Margin
- 56.36%
- Net Margin
- 82.37%
- ROE
- 2515.23%
- ROIC
- 47.19%
Latest fiscal year · YoY change
- Revenue
- $234.60M+157.0%
- Gross Profit
- $232.18M+420.0%
- Op Income
- $47.90M
- Net Income
- $-13,232,000+90.9%
- EPS
- $-0.46+91.0%
- OCF Growth
- +114.6%
- FCF Growth
- +114.5%
- 52W High
- $72.36
- 52W Low
- $19.65
- 50D MA
- $54.88
- 200D MA
- $48.89
- Beta
- 0.41
- RSI (14)
- 33
- Avg Volume
- 574.56K
No earnings-call transcripts are available for ANAB yet.
- Free Float
- 93.7%
- Shares Outstanding
- 29.61M
- Float Shares
- 27.75M
of shares held by institutions
221 13F filers
Buy/sell ratio 0.50. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Ecor1 Capital, LLC | 7.88M | 0 |
| Blackrock, Inc. | 1.84M | ▲ 162.67K |
| Vanguard Group Inc | 1.54M | ▲ 67.05K |
| Tang Capital Management LLC | 1.33M | 0 |
| State Street Corp | 1.29M | ▲ 293.75K |
| Vanguard Capital Management LLC | 906.23K | ▲ 53.08K |
| Affinity Asset Advisors, LLC | 826.11K | ▼ 113.89K |
| Sanofi | 821.92K | 0 |
| Millennium Management LLC | 807.32K | ▲ 331.74K |
| Woodline Partners LP | 717.01K | ▲ 372.76K |
| 683 Capital Management, LLC | 660.00K | ▲ 35.00K |
| Geode Capital Management, LLC | 637.87K | ▲ 117.63K |
Held by 265 ETFs
Biggest fund positions in ANAB by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Oct 1, 26 | RENTON HOLLINGS | other | 5,000 |
| Oct 1, 26 | RENTON HOLLINGS | sell | 5,000 |
| Oct 1, 26 | RENTON HOLLINGS | other | 5,000 |
| Sep 15, 26 | Orwin John A | other | 1,300 |
| Sep 15, 26 | Orwin John A | other | 1,300 |
| Mar 12, 26 | Lizzul Paul F. | other | 16,667 |
| Mar 12, 26 | Faga Daniel | other | 53,334 |
| Jun 15, 26 | Schmid John P. | other | 6,030 |
| Jun 15, 26 | Schmid John P. | other | 6,030 |
| Jun 15, 26 | RENTON HOLLINGS | other | 6,030 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our ANAB coverage
Recent articles, reports, and earnings notes.
No research on ANAB yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate ANAB report →AnaptysBio, Inc. (ANAB) Reports Q2 Loss, Tops Revenue Estimates
zacks.com · Sep 21
Anaptys Announces Second Quarter and Transitional Fiscal Year 2026 Financial Results and Provides Business Update
globenewswire.com · Sep 21
Anaptys Announces Participation at the H.C. Wainwright 28th Annual Global Investment Conference
globenewswire.com · Sep 1
16,500 Shares in AnaptysBio, Inc. $ANAB Bought by Canada Pension Plan Investment Board
defenseworld.net · Sep 1
GSK's sBLA for Jemperli Gets FDA Priority Tag in Rectal Cancer
zacks.com · Aug 24
AnaptysBio: The Royalty Waterfall Is About To Reverse
seekingalpha.com · Jul 29
AnaptysBio (NASDAQ:ANAB) Stock Price Up 5.3% – Still a Buy?
defenseworld.net · Jul 19
GSK's Jemperli Delivers Promising Interim Data in Rectal Cancer
zacks.com · Jul 14
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.